EcoDrugPlus

Egl Nine Homolog 3-Like

Ensembl ID : ENSAOCG00000023534
Gene Symbol: LOC111586571
3 Cross references
196 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSAOCG00000000803
Gene Symbol: EGLN1
3 Cross references
216 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSAOCG00000012038
Gene Symbol: ECE1
3 Cross references
231 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSAOCG00000001021
Gene Symbol: EDNRB
3 Cross references
200 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSAOCG00000014365
Gene Symbol: EDNRB
3 Cross references
178 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSAOCG00000000075
Gene Symbol: LOC111563245
3 Cross references
205 Possible Orthologues:

Endothelin-1 Receptor-Like

Ensembl ID : ENSAOCG00000010739
Gene Symbol: LOC111583537
3 Cross references
201 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSAOCG00000008731
Gene Symbol: EZH2
3 Cross references
240 Possible Orthologues:

Ephrin Type-B Receptor 4-Like

Ensembl ID : ENSAOCG00000015296
Gene Symbol: LOC111584156
3 Cross references
167 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSAOCG00000006328
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSAOCG00000008233
Gene Symbol: EPHX2
3 Cross references
204 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSAOCG00000021622
Gene Symbol: LOC111562720
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).